Renaissance Technologies
FENC icon

Renaissance Technologies’s Fennec Pharmaceuticals FENC Stock Holding History

Renaissance Technologies’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$154K – 3384
2025
Q4 		$154K Buy
20,000
+9,400
+89% +$77.2K ﹤0.01% 2932
2025
Q3 		$99.2K Buy
+10,600
New +$91.8K ﹤0.01% 3251
2024
Q2 		– Sell
-139,900
Closed -$1.56M – 3639
2024
Q1 		$1.56M Buy
+139,900
New +$1.4M ﹤0.01% 2195
2021
Q3 		– Sell
-20,284
Closed -$148K – 3575
2021
Q2 		$148K Buy
+20,284
New +$135K ﹤0.01% 3307
2020
Q3 		– Sell
-134,000
Closed -$1.12M – 3461
2020
Q2 		$1.12M Buy
134,000
+57,904
+76% +$431K ﹤0.01% 2489
2020
Q1 		$452K Buy
76,096
+52,296
+220% +$341K ﹤0.01% 2805
2019
Q4 		$154K Buy
+23,800
New +$128K ﹤0.01% 3245
2019
Q2 		– Sell
-31,100
Closed -$151K – 3609
2019
Q1 		$151K Buy
+31,100
New +$204K ﹤0.01% 3247
2018
Q2 		– Sell
-34,800
Closed -$421K – 3348
2018
Q1 		$421K Buy
+34,800
New +$329K ﹤0.01% 2968

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Renaissance Technologies's FENC Position: Q1 2026 in Review

Renaissance Technologies sold out of Fennec Pharmaceuticals (FENC) in Q1 2026, closing a stake of 20,000 shares — an estimated $154K sold.

Renaissance Technologies first reported a position in FENC in Q1 2018 and held it in 9 quarters. The position peaked at $1.56M in Q1 2024. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Renaissance Technologies reported no remaining Fennec Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Renaissance Technologies sold 20,000 Fennec Pharmaceuticals shares in Q1 2026, an estimated $154K.
  • Renaissance Technologies first reported a position in Fennec Pharmaceuticals in Q1 2018 and held it in 9 quarters.
  • Renaissance Technologies's Fennec Pharmaceuticals position peaked at $1.56M in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.